The overall objective of this proposal is to define the cellular mechanisms contributing to carcinogenesis of cholangiocytes, the epithelia cells lining the biliary system. Chronic inflammation of the biliary tree predisposes patients to the development of cholangiocarcinoma. Because of this relationship, our long term goal is to understand the mechanisms by which inflammatory mediators contribute to the development and progression of cholangiocarcinoma. We have recently generated striking preliminary data demonstrating that cholangiocarcinomas paradoxically express the potent apoptosis inducing ligand TRAIL. However, because the inflammatory mediator IL-6 upregulates the anti-apoptotic protein Mcl-1, they are resistant to TRAIL cytotoxicity. These same characteristics, paradoxical TRAIL expression and upregulation of Mcl-1, were also identified in a newly described genetic murine model of cholangiocarcinoma. Based on these extensive preliminary data, we propose the central hypothesis that the inflammatory cytokine IL-6 upregulates Mcl-1, which in turn circumvents TRAIL cytotoxicity. Our proposal has three specific aims. First, we will test the hypothesis that IL-6 upregulates Mcl-1 by both transcriptional and post-translational mechanisms due to SOCS3 silencing and Akt-mediated Mcl-1 phosphorylation, respectively. Second, we will test the hypothesis that Mcl-1 inhibits TRAIL-mediated apoptosis by binding specific pro-apoptotic BH3- only proteins of the Bcl-2 family, thereby, blocking the lysosomal pathway of cell death. Finally, we will test the hypothesis that Mcl-1 expression and function can be inhibited in a murine model of cholangiocarcinoma, resulting in tumor autonomous, TRAIL-mediated apoptosis. To address these questions, we have established cholangiocarcinoma cell lines that differentially express Mcl-1 and have become adept at dissecting IL-6 and TRAIL signaling pathways. We have also developed an understanding of Mcl-1 structure and function relationships. Finally, we have developed a collaboration to test the proposed concepts in a recently described murine model of cholangiocarcinoma. The proposal is conceptually and technically innovative as it tests new concepts as to how inflammatory mediators promote a major cancer phenotype, evasion of apoptosis. The information emanating from these studies may potentially help identify therapeutic strategies for the treatment and/or chemoprevention of cholangiocarcinoma.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK059427-10
Application #
7821353
Study Section
Special Emphasis Panel (ZRG1-DIG-C (02))
Program Officer
Doo, Edward
Project Start
2001-07-01
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
10
Fiscal Year
2010
Total Cost
$270,472
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Rizvi, Sumera; Yang, Ju Dong; Gores, Gregory J (2017) Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis? Gut 66:4-5
Hirsova, Petra; Guicciardi, Maria Eugenia; Gores, Gregory J (2017) Proapoptotic signaling induced by deletion of receptor-interacting kinase 1 and TNF receptor-associated factor 2 results in liver carcinogenesis. Hepatology 66:983-985
Fan, Wei; Yang, Heping; Liu, Ting et al. (2017) Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells. Hepatology 65:1249-1266
Rizvi, Sumera; Gores, Gregory J (2017) Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol 67:632-644
Eaton, John E; Dzyubak, Bogdan; Venkatesh, Sudhakar K et al. (2016) Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol 31:1184-90
Razumilava, Nataliya; Gores, Gregory J (2016) Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified? Clin Liver Dis (Hoboken) 8:43-47
Rizvi, Sumera; Yamada, Daisaku; Hirsova, Petra et al. (2016) A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem 291:8031-47
Yang, Heping; Liu, Ting; Wang, Jiaohong et al. (2016) Deregulated methionine adenosyltransferase ?1, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans(‡). Hepatology 64:439-55
Rizvi, Sumera; Gores, Gregory J (2016) Liver capsule: Cholangiocarcinoma (CCA). Hepatology 63:1356
Borad, Mitesh J; Gores, Gregory J; Roberts, Lewis R (2015) Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. Curr Opin Gastroenterol 31:264-8

Showing the most recent 10 out of 53 publications